Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia
Stopped early · Phase 1
Conditions studied: Leukemia, Lymphocytic, Acute, Leukemia, Acute Lymphoid Leukemia (ALL)
In brief
This is a phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. The trial will study the safety, pharmacokinetics, and anti-tumor activity of the antibody given as a single agent and with vincristine.
Key facts
- Study ID
- NCT00313053
- Run by
- Clare Twist
- People needed
- 4
- Starts
- 2004-09-01
- Expected to finish
- 2008-07-01
- Last updated by the study team
- 2016-06-03
Who can join
Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.